Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.
In season 1, episode 1 of Targeted Talks, community physician Jason R. Williams, MD, DABR, interventional radiologist, Williams Cancer Institute, leads a discussion with George R. Simon, MD, FACP, FCCP, medical oncologist, The University of Texas MD Anderson Cancer Center, about the use of immunotherapy in patients with non–small cell lung cancer (NSCLC), whether treated in an academic or community setting, and how this could be challenged with the discovery of a genetic driver alteration.
During the discussion, the 2 experts cover the pros and cons of immunotherapy use and how they differ in the community setting versus the academic setting, the available tools for profiling patients, promising immune checkpoint inhibitors for the treatment of NSCLC, key genetic drivers in NSCLC, and choosing the optimal subsequent therapy for patients with NSCLC.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More